Clinical trials: HCM
Healthy
Single Ascending Dose Study of MYK-461 in Healthy Volunteers
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects.
- Trial name
- NCT02356289
- Testing
- MYK-461
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MyoKardia, Inc.
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- NCT07367724
- Testing
- Ademetionine 1,4-Butanedisulfonate
- Where
- 3 sites in China
- Volunteers
- 44 people
- Sponsor
- China National Center for Cardiovascular Diseases
Carnitine Deficiency
Identification of Carnitine-Responsive Cardiomyopathy
There are some adults with skeletal muscle weakness (called "myopathy") and heart muscle weakness (called "cardiomyopathy") who have low blood levels of a compound called carnitine as a cause of their problems.
- Trial name
- C001 (NCT01904396)
- Testing
- Carnitine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Hypertrophic Cardiomyopathy Without Obstruction
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
The goal of this clinical trial is to learn if sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, works to treat symptomatic, nonobstructive hypertrophic cardiomyopathy (noHCM) in adult patients.
- Trial name
- SOTA-CROSS HCM (NCT06433050)
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
- Trial name
- NCT07107373
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Obstructive Cardiomyopathy
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
Objective of the study: to evaluate whether edge-to-edge technique improves clinical and hemodynamic results in patients scheduled to septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy.
- Trial name
- PRIZMA-pilot (NCT04470102)
- Testing
- mitral valve repair by edge-to-edge technique, Septal myectomy
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Healthy Participants
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
The purpose of this study is to evaluate the effects on the single-dose drug levels of mavacamten in healthy participants.
- Trial name
- NCT05362045
- Testing
- Mavacamten
- Where
- 4 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with…
- Trial name
- SILICOFCM (NCT03832660)
- Testing
- Lifestyle, Sacubitril/Valsartan
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 168 people
- Sponsor
- Newcastle University
Hypertrophic Cardiomyopathy (HCM)
Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy
This study will review medical information collected on children and adolescents with hypertrophic cardiomyopathy (HCM) to try to identify risk factors for arrhythmias (abnormal heart rhythms) in these patients and better guide…
- Trial name
- NCT00753233
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
HCM - Hypertrophic Cardiomyopathy, Sudden Cardiac Death
Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy
Pilot interventional randomized clinical trial to study the efficacy of left bundle branch pacing in patients with hypertrophic cardiomyopathy after myectomy for the prevention of progression of heart failure, prevent the…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Sudden Cardiac Death, Left Bundle Branch Pacing, ICD
- Trial name
- LEFTpaceHCM (NCT07372196)
- Testing
- ICD with left bundle branch area pacing (LBBAP), dual-chamber ICD
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Hypertrophic Cardiomyopathy
French Hypertrophic Cardiomyopathy Observatory
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified.
- Trial name
- REMY (NCT01091480)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- French Cardiology Society
Hypertrophic Cardiomyopathy
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and…
- Trial name
- EXCITE-HCM (NCT05818605)
- Testing
- Moderate Intensity Exercise Program
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Hypertrophic Cardiomyopathy, Obstruction
4D-flow MRI to Assess Left Ventricular Obstruction in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a frequent cardiac pathology with an estimated prevalence of 1/500 in France. The main risk factor for sudden death in this pathology is the presence and extent of left ventricular…
- Conditions
- Hypertrophic Cardiomyopathy, Obstruction, Echocardiography
- Trial name
- CMHFLUX (NCT04439942)
- Testing
- cardiac magnetic resonance imaging (MRI)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hypertrophic Cardiomyopathy
Renal Denervation in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is the most common inherited monogenic heart disease. There is an abnormal increase in myocardial mass in this disorder that leads to a state of cardiac sympathetic hypertonia, which is involved…
- Trial name
- SNYPER-PS (NCT05577208)
- Testing
- "Symplicity Spyral" multi-electrode renal denervation catheter and "Symplicity G3" generator (Renal Denervation System)
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Adolfo Fontenla
Obstructive Hypertrophic Cardiomyopathy
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
This prospective, multicenter, single-arm objective performance criteria trial is designed to assess the efficacy and safety of the Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) procedure in the treatment of…
- Trial name
- NCT06224621
- Testing
- Percutaneous Endocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- China National Center for Cardiovascular Diseases
Hypertrophic Cardiomyopathy
Mitral Valve Management During Septal Myectomy
Objective of the study: to evaluate whether alfieri technique improves clinical and hemodynamic results compared to transaortic mitral valve secondary cord cutting in patients scheduled to septal myectomy for severely symptomatic…
- Trial name
- MVMSM (NCT03906734)
- Testing
- Septal myectomy, alfieri stich, Subvalvular intervention
- Where
- Russia
- Volunteers
- 48 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Obstructive Hypertrophic Cardiomyopathy
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
The present trial is undertaken as a pilot study on selected patients, to evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of Obstructive Hypertrophic Cardiomyopathy (OHCM)…
- Trial name
- PACE-OHCM (NCT05771987)
- Testing
- pace maker implant guided by acute hemodynamic testing
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Istituto Auxologico Italiano
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)
Hypertrophic Obstructive Cardiomyopathy (HOCM) is an inherited cardiac condition which causes the heart muscle to become abnormally thick causing obstruction of blood flow in the heart.
- Trial name
- EMORI-HCM (NCT05257772)
- Testing
- AV Delay Optimised RV Pacing
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
COVID-19, Cardiomyopathies
The Heart Hive COVID-19 Study
All patients with heart disease should have the opportunity to participate in research into their condition, to advance knowledge and treatment.
- Trial name
- NCT04468256
- Testing
- COVID-19 experience surveys
- Where
- United Kingdom
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Use of SGLT2i in noHCM With HFpEF
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of…
- Trial name
- NCT06401343
- Testing
- Empagliflozin 10 MG
- Where
- China
- Volunteers
- 94 people
- Sponsor
- China National Center for Cardiovascular Diseases